Atjaunināt sīkdatņu piekrišanu

E-grāmata: Nanotherapeutics for Infectious Diseases

  • Formāts: 432 pages
  • Izdošanas datums: 15-Apr-2025
  • Izdevniecība: Jenny Stanford Publishing
  • Valoda: eng
  • ISBN-13: 9781040263570
  • Formāts - PDF+DRM
  • Cena: 174,07 €*
  • * ši ir gala cena, t.i., netiek piemērotas nekādas papildus atlaides
  • Ielikt grozā
  • Pievienot vēlmju sarakstam
  • Šī e-grāmata paredzēta tikai personīgai lietošanai. E-grāmatas nav iespējams atgriezt un nauda par iegādātajām e-grāmatām netiek atmaksāta.
  • Bibliotēkām
  • Formāts: 432 pages
  • Izdošanas datums: 15-Apr-2025
  • Izdevniecība: Jenny Stanford Publishing
  • Valoda: eng
  • ISBN-13: 9781040263570

DRM restrictions

  • Kopēšana (kopēt/ievietot):

    nav atļauts

  • Drukāšana:

    nav atļauts

  • Lietošana:

    Digitālo tiesību pārvaldība (Digital Rights Management (DRM))
    Izdevējs ir piegādājis šo grāmatu šifrētā veidā, kas nozīmē, ka jums ir jāinstalē bezmaksas programmatūra, lai to atbloķētu un lasītu. Lai lasītu šo e-grāmatu, jums ir jāizveido Adobe ID. Vairāk informācijas šeit. E-grāmatu var lasīt un lejupielādēt līdz 6 ierīcēm (vienam lietotājam ar vienu un to pašu Adobe ID).

    Nepieciešamā programmatūra
    Lai lasītu šo e-grāmatu mobilajā ierīcē (tālrunī vai planšetdatorā), jums būs jāinstalē šī bezmaksas lietotne: PocketBook Reader (iOS / Android)

    Lai lejupielādētu un lasītu šo e-grāmatu datorā vai Mac datorā, jums ir nepieciešamid Adobe Digital Editions (šī ir bezmaksas lietotne, kas īpaši izstrādāta e-grāmatām. Tā nav tas pats, kas Adobe Reader, kas, iespējams, jau ir jūsu datorā.)

    Jūs nevarat lasīt šo e-grāmatu, izmantojot Amazon Kindle.

This book is more than just a compilation of nanomaterials used for the treatment and prevention of infectious diseases. It starts by tracing the historical trajectory of the nanomedicine field, charting its evolution to the present day.



The study of materials at the nanoscale, characterized by their exceptional physicochemical properties, and their interactions with biological systems have greatly impacted the healthcare sector and the pharmaceutical industry. This book is more than just a compilation of nanomaterials used for the treatment and prevention of infectious diseases. It starts by tracing the historical trajectory of the nanomedicine field, charting its evolution to the present day. This is followed by two additional introductory chapters, one offering an overview of clinically approved nanoformulations for human use and another contextualizing the current landscape of infectious diseases. Subsequent chapters delve into the utilization of nanotherapeutics in the treatment and prevention of infections caused by various pathogens (such as viruses, bacteria, parasites, and fungi). The book also features focused chapters on COVID-19 and malaria, illustrating how nanotherapeutics contribute to the clinical management of these prevalent global health priorities.

1. Nanomedicine: A Historical Perspective
2. Clinically Approved Nanotherapeutics
3. High-Priority Pathogens: Where Do We Stand?
4. Overview of Nanotherapeutics for Viral Infections
5. Formulation Approaches for COVID-19 Vaccines
6. Overview of Nanotherapeutics for Bacterial Infections
7. Nanotechnology Applied to Tackle Malaria
8. Overview of Nanotherapeutics for Fungal Infections
9. Biogenic and Biomimetic Nanocarriers

Ķris Luz Batalha is currently a junior leader research fellow at the Institute for Bioengineering of Catalonia (IBEC) in Barcelona, a course director in nanotherapeutics at the University of Cambridge Institute of Continuing Education, a freelance senior innovation strategy consultant, a co-founder and director of the non-profit organization Women Ahead of Their Time (WATT), and a research associate at Peterhouse College. From 2017 to 2020, she was a joint research associate at the Department of Engineering Nanoscience Centre and Department of Medicine Molecular Immunity Unit, University of Cambridge. From 2014 to 2017, she worked at the Department of Chemical Engineering and Biotechnology, University of Cambridge, and the biopharmaceutical company MedImmune/AstraZeneca, followed by a brief experience as a healthcare/pharmaceutical competitive intelligence consultant. Her research interests and expertise lie in medical and pharmaceutical research and development, particularly in the fields of nanobiotechnology, bioinspired materials, downstream processing, formulation, and drug delivery.